Testing of Schistosoma mansoni Vaccine Targets

• DOI: 10.1007/978-1-0716-0635-3_19
• Publication Date: 2020-05-25T11:02:38Z
• Authors: Weidong Zhang; Adebayo Molehin; Parth Patel; Eunjee Kim; Adam Peña; Afzal A. Siddiqui
• Keywords: Primates; Immunity, Cellular; Vaccines; Enzyme-Linked Immunosorbent Assay; Schistosoma mansoni; Immunity, Humoral; 3. Good health; Mice, Inbred C57BL; Perfusion; Disease Models, Animal; Feces; Animals; Female; Parasites; Ovum

Vaccination has greatly reduced the burden of human diseases caused by infectious pathogens. Systematic development of vaccine targets requires established protocols to assess immunogenicity and efficacy of such vaccine candidates. Using a leading schistosomiasis vaccine candidate, Sm-p80, as an example, we describe standardized approaches for testing the immunogenicity and efficacy of Schistosoma mansoni vaccine targets. Unlike other parasite systems in which sterile immunity is required, the goal of S. mansoni vaccine targets is overall reduction in morbidity. Methods related to the parasitological parameters described in this chapter allow for the testing of the prophylactic (reduction in adult worm burden), anti-pathology (liver and intestine egg retention), and transmission blocking (fecal egg expulsion and egg hatching rates) efficacies for the vaccine target. The RNA sequencing approaches provide basis for identification of molecular signatures predictive of desirable outcomes for schistosomiasis vaccines.